← Eichor
Study identifier: NCT07154667 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction

Condition: Microtia, Congenital · Microtia · Microtia-Anotia  ·  Sponsor: Nemours Children's Clinic

PhaseNA
Planned participants30
Who can joinAll sexes, 5 Years to 20 Years
Healthy volunteersNo

About this study

This study aims to improve surgical outcomes for children and young adults with ear differences severe secondary to congenital conditions (like microtia, a condition where the ear is underdeveloped), trauma (such as dog bites), or surgical resections secondary to skin cancer. The investigators have developed a novel medical device to shape cartilage into pre-determined shapes that, once assembled, assists the surgeon in creating an anatomically accurate cartilaginous ear framework, reduce surgery time, and minimize wire need. Other factors that might affect the quality of surgical outcomes will be examined in clinical trial participants.

This description comes directly from the study's public registry record.

Talk to the study team

Heaven Sippio - Executive Assistant  ·  407-650-7358  ·  heaven.sippio@nemours.org

Ishpriya Sharma - Research Project Specialist, PhD  ·  ishpriya.sharma@nemours.org

Always discuss trial participation with your own doctor first.

Locations (1)

Nemours Children's Hospital, FloridaOrlando, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07154667